ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,019.05
-0.31%
Dow Jones
44,471.38
-0.19%
US Dollar vs MXN
20.66165
0.71%
Brent Oil
74.95
-1.30%
Bitcoin
98,253.98
0.41%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Syros Pharmaceuticals Inc (SYRS)

  7. Syros Pharmaceuticals Inc (SYRS) Noticias

SYRS

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SYRS
FechaHoraFuenteTítuloSímboloCompañía
16/01/202515:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202515:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
20/11/202416:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
14/11/202416:28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
12/11/202415:30Business WireSyros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene OverexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
31/10/202406:30Business WireSyros Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
31/10/202405:49Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRSSyros Pharmaceuticals Inc
24/10/202406:08Business WireSyros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
27/08/202406:00Business WireSyros Pharmaceuticals to Present at Upcoming Medical and Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
12/08/202415:15Business WireSyros Provides Update on SELECT-AML-1 Phase 2 Clinical TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
31/07/202406:44Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRSSyros Pharmaceuticals Inc
31/07/202406:30Business WireSyros Reports Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
24/07/202406:00Business WireSyros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
13/06/202406:00Business WireSyros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene OverexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
14/05/202406:30Business WireSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202408:00Business WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
07/05/202406:00Business WireSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
09/04/202406:00Business WireSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
02/04/202415:30Business WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202406:30Business WireSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
27/03/202405:57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:SYRSSyros Pharmaceuticals Inc
25/03/202406:00Business WireSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
20/03/202406:00Business WireSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
27/02/202406:00Business WireSyros to Participate in TD Cowen 44th Annual Health Care ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
14/02/202419:56Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
13/02/202419:22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
08/01/202406:00Business WireSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of TamibaroteneNASDAQ:SYRSSyros Pharmaceuticals Inc
26/12/202316:19Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202315:53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRSSyros Pharmaceuticals Inc
19/12/202306:27Business WireSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:SYRSSyros Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SYRS

Su Consulta Reciente

COIN
ADAUSD
Cardano
NYSE
NKE
Nike
CCOM
SILVER
SILVER
NASDAQ
MSFT
Microsoft
COIN
ETHUSD
Ethereum
CCOM
US500
US 500
COIN
XRPUSD
Ripple
COIN
BTCUSD
Bitcoin
USOTC
BASFY
BASF (QX)
NYSE
VZ
Verizon Communications
AMEX
XLE
Energy Select Sector SPDR
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
BAC
Bank of America
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios